Physician profile
Kelly Freund
NPI 1619248325
$4,229.22
in general payments reported to CMS, 2019-2025
25 companies · $942 in 2025
The $942 reported for 2025 was more than what 82% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $892 · 2022: $738 · 2023: $779 · 2024: $879 · 2025: $942.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,300 · Education: $300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,299.98 |
| Education | $300.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $924.42 | 2021-2025 | |
| Collegium Pharmaceutical, INC. | $589.22 | 2021-2025 | Belbuca, Xtampza |
| Tersera Therapeutics LLC | $559.36 | 2024-2025 | Prialt |
| Novo Nordisk INC | $445.95 | 2021-2025 | Ozempic, Rybelsus |
| Averitas Pharma INC. | $335.64 | 2023-2025 | Qutenza |
| Pfizer INC. | $187.61 | 2021-2025 | |
| Lundbeck LLC | $167.01 | 2021-2025 | Vyepti |
| Amgen INC. | $166.96 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $95.14 | 2022 | |
| Lilly USA, LLC | $89.85 | 2021-2025 | Mounjaro, Zepbound, Emgality |
| Nevro Corp. | $82.97 | 2021-2024 | Senza |
| Biohaven Pharmaceuticals, INC. | $72.32 | 2021 | |
| Medtronic, INC. | $71.19 | 2021-2025 | Inceptiv |
| Vertex Pharmaceuticals Incorporated | $71.16 | 2025 | |
| Idorsia Pharmaceuticals US INC | $68.62 | 2023-2024 | Quviviq |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $62.11 | 2021-2022 | |
| Si-Bone, INC. | $58.90 | 2021-2025 | |
| Protega Pharmaceutials INC | $42.56 | 2025 | Roxybond |
| Ibsa Pharma INC. | $42.20 | 2021-2024 | Tirosint, Tirosint, Flector |
| Kowa Pharmaceuticals America, INC. | $19.80 | 2022 | |
| Virtus Pharmaceuticals LLC | $17.07 | 2021 | |
| Novartis Pharmaceuticals Corporation | $16.50 | 2021 | |
| Globus Medical, INC. | $15.92 | 2025 | Senza |
| Currax Pharmaceuticals LLC | $13.67 | 2023 | Onzetra Xsail, Contrave |
| Eisai INC. | $13.07 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelly Freund listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.